ClinicalTrials.gg
CompletedNCT01001702Updated Sep 27, 2013Results posted

Oral Aripiprazole Open-Label Rollover Study

A Phase 3 interventional study of Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 15 sites in 6 countries. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2013-09-27.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
76th of 125
85 · median 130
Started
2006
with 7 others
Phase 3
34 of 126
1 open now
Registered
58th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 76th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2006, is one of 34 in phase 3, and was the 58th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Open Label
  • Aripiprazole
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a confirmed Axis I , Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia

Exclusion criteria

Exclusion Criteria:

  • Patients with a co-morbid serious, uncontrolled systemic illness
  • Patients with a significant risk of committing suicide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Oral Aripiprazole

    Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.

    Drug: Aripiprazole

Interventions

  • Flexible dose between 5 mg and 30 mg Aripiprazole tablets.

    Also known as: ABILIFY®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths

    An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention. Additional information about Adverse Events can be found in the Adverse Event section.

    Time frame: Up to 72 months

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score

    The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement

    Time frame: Baseline, Last Visit (Up to 72 Months)

  2. Number of Participants With Clinical Significant Laboratory Tests

    Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory. Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase \> 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years \[Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)\]. Eosinophils ≥ 10 %. Hematocrit \< 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline. Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin \> 1 times the upper limit of normal \[Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)\].

    Time frame: Baseline, Up to 72 Months

  3. Number of Participants With Clinically Significant Heart Rate

    Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing. A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline. A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.

    Time frame: Baseline, Up to 72 months

  4. Number of Participants With Clinically Significant Blood Pressure

    Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing. Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline. A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline.

    Time frame: Baseline, Up to 72 months

  5. Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations

    A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged. Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline. Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline. Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline.

    Time frame: Baseline, Up to 72 months

  6. Number of Participants Showing Significant Weight Gain or Loss

    Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72. A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline. A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.

    Time frame: Baseline, Up to 72 months

  7. Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit. Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity). The number of participants experiencing suicidal ideation or suicidal behavior is reported.

    Time frame: Baseline, Up to 72 months

07

Results

Posted Sep 27, 2013

Participant flow

Participant flow — Overall Study
MilestoneOral Aripiprazole
Started85
Completed13
Not completed72
Withdrew: Lost to follow-up7
Withdrew: Adverse event7
Withdrew: Sponsor discontinued study4
Withdrew: Subject met withdrawal criteria22
Withdrew: Investigator withdrew subject10
Withdrew: Withdrawal by subject19
Withdrew: Lack of efficacy per investigator3

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths

An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention. Additional information about Adverse Events can be found in the Adverse Event section.

Time frame:
Up to 72 months
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
ParticipantsOral Aripiprazole
AEs61
SAEs11
Discontinuation due to AEs7
Death1
SecondaryChange From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score

The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement

Time frame:
Baseline, Last Visit (Up to 72 Months)
Reported as:
Mean · Score on a scale
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score
Score on a scaleOral Aripiprazole
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score-0.26 ± 1.07
SecondaryNumber of Participants With Clinical Significant Laboratory Tests

Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory. Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase \> 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years \[Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)\]. Eosinophils ≥ 10 %. Hematocrit \< 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline. Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin \> 1 times the upper limit of normal \[Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)\].

Time frame:
Baseline, Up to 72 Months
Reported as:
Number · Participants
Number of Participants With Clinical Significant Laboratory Tests
ParticipantsOral Aripiprazole
Bilirubin, total (mg/dL)7
Creatine phosphokinase (CPK), total (IU/L)6
Eosinophils (%)5
Hematocrit (%)5
Hemoglobin (g/dL)3
Prolactin (ng/mL)3
SecondaryNumber of Participants With Clinically Significant Heart Rate

Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing. A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline. A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.

Time frame:
Baseline, Up to 72 months
Reported as:
Number · Participants
Number of Participants With Clinically Significant Heart Rate
ParticipantsOral Aripiprazole
Supine Heart Rate Increase0
Supine Heart Rate Decrease0
Standing Heart Rate Increase1
Standing Heart Rate Decrease0
SecondaryNumber of Participants With Clinically Significant Blood Pressure

Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing. Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline. A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline.

Time frame:
Baseline, Up to 72 months
Reported as:
Number · Participants
Number of Participants With Clinically Significant Blood Pressure
ParticipantsOral Aripiprazole
Supine Systolic Blood Pressure Increase4
Supine Systolic Blood Pressure Decrease3
Standing Systolic Blood Pressure Increase5
Standing Systolic Blood Pressure Decrease2
Supine Diastolic Blood Pressure Increase5
Supine Diastolic Blood Pressure Decrease0
Standing Diastolic Blood Pressure Increase5
Standing Diastolic Blood Pressure Decrease0
SecondaryNumber of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations

A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged. Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline. Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline. Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline.

Time frame:
Baseline, Up to 72 months
Reported as:
Number · Participants
Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations
ParticipantsOral Aripiprazole
Sinus bradycardia7
Supraventricular premature beat6
Ventricular premature beat1
Right bundle branch block1
Other intraventricular block5
Symmetrical T-wave inversion1
QTcB9
QTcF4
QTcN6
QTcE5
SecondaryNumber of Participants Showing Significant Weight Gain or Loss

Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72. A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline. A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.

Time frame:
Baseline, Up to 72 months
Reported as:
Number · Participants
Number of Participants Showing Significant Weight Gain or Loss
ParticipantsOral Aripiprazole
Weight Gain37
Weight Loss4
SecondaryNumber of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit. Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity). The number of participants experiencing suicidal ideation or suicidal behavior is reported.

Time frame:
Baseline, Up to 72 months
Reported as:
Number · Participants
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsOral Aripiprazole
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Aripiprazole—11/85 (12.9%)45/85 (52.9%)
Most frequent serious events
Most frequent serious events
EventOral Aripiprazole
Suicide attemptPsychiatric disorders3/85
SchizophreniaPsychiatric disorders2/85
Pneumonia bacterialInfections and infestations1/85
Ligament ruptureInjury, poisoning and procedural complications1/85
Psychomotor hyperactivityNervous system disorders1/85
AggressionPsychiatric disorders1/85
Impulsive behaviourPsychiatric disorders1/85
Psychotic disorderPsychiatric disorders1/85
Social stay hospitalisationSocial circumstances1/85
Most frequent other events
Showing 10 of 12
Most frequent other events
EventOral Aripiprazole
HeadacheNervous system disorders13/85
InfluenzaInfections and infestations9/85
Weight increasedInvestigations9/85
PyrexiaGeneral disorders8/85
VomitingGastrointestinal disorders7/85
PainGeneral disorders7/85
NasopharyngitisInfections and infestations6/85
NauseaGastrointestinal disorders5/85
Decreased appetiteMetabolism and nutrition disorders5/85
SomnolenceNervous system disorders5/85

Baseline characteristics

Age Continuous
Age Continuous(years)Oral Aripiprazole
Mean16.29 ± 1.36
Sex: Female, Male
Sex: Female, Male(Participants)Oral Aripiprazole
Female42
Male43
08

Study locations

15 sites
  • Study site
    Buenos Aires, Argentina
  • Study site
    Mendoza, Argentina
  • Study site
    Split, Croatia
  • Study site
    Hyderabad, India
  • Study site
    Ludhiana, India
  • Study site
    Mumbai, India
  • Study site
    Tamilnadu, India
  • Study site
    Moscow, Russian Federation
  • Study site
    Rostov-on-Don, Russian Federation
  • Study site
    St.Petersburg, Russian Federation
  • Study site
    Yaroslavl, Russian Federation
  • Study site
    Belgrade, Serbia
  • Study site
    Novi Sad, Serbia
  • Study site
    Kharkiv, Ukraine
  • Study site
    Kiev, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2009
First posted
Oct 27, 2009
Start
Apr 2006
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Sep 27, 2013
Last update
Sep 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01001702
Responsible party
Sponsor
First posted
Oct 27, 2009
Start date
Apr 2006
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Sep 27, 2013
Last update
Sep 27, 2013
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion